Transfer of the Company's own shares
Revenio Group Corporation has transferred on May 26, 2021 1,046 shares (REG1V) to the members of the Board of Directors as part of remuneration of the Board.
Revenio Group Corporation's AGM decided on March 17, 2021 that 40% of the fee paid to a board member should be paid in company shares while 60% will comprise a monetary payment. The AGM decided that the Chair of the Board be entitled to an annual emolument of EUR 48,000, the Board members who act as the Chairman of the Committee be entitled to an annual emolument of EUR 30,000 and the other Board members to an annual emolument of EUR 24,000. The share payment will be valued using the weighted average value of the share on the day following the release of the Interim Report January 1- March 31, 2021.
As a result of these transfers, the share-based board member fees have been completely settled for the year 2021. Revenio Group Corporation now holds a total of 111,546 of its own shares.
Revenio Group Corporation
Board of Directors
For further information, please contact:
Jouni Toijala, CEO, tel. +358 50 484 0085
Nasdaq Helsinki Oy
Financial Supervisory Authority (FIN-FSA)
Revenio Group in brief
Revenio is a global leader in ophthalmological devices and solutions. Revenio Group's ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), retinal imaging devices, and perimeters under the iCare brand. In addition, Revenio Group’s eye care software platform Oculo combines clinical communication, telehealth, remote patient monitoring and data-analytics capabilities.
The Revenio Group comprises Revenio Group Corporation, Icare Finland Oy, Icare USA Inc., Revenio Italy S. R. L, CenterVue SpA, Revenio Research Oy, Revenio Australia Pty Ltd, Done Medical Oy, and Oscare Medical Oy.
In 2020, the Group's net sales totaled EUR 61.1 million, with its operating profit standing at MEUR 17.1. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.